vaccine

Local biotech firm Moderna Inc. has indicated its COVID-19 vaccine could be one of the most expensive in the industry. Executives from the Cambridge-based company discussed the commercialization plans for its COVID-19 vaccine, mRNA-1273, and other business updates during the company’s second quarter earnings call Wednesday. There were four key takeaways from the call. Read more at the Boston...

Who will be first in line for a COVID-19 vaccine

Dr. Anthony Fauci says a possible coronavirus vaccine entering a phase three trial has been promising.

The U.S. government will pay drugmakers Sanofi and GlaxoSmithKline up to $2.1 billion to develop and deliver 100 million doses of their potential coronavirus vaccine, the companies announced Friday. More than half of the $1.5 billion will be used to support further development of the vaccine, including clinical trials. The rest will be for manufacturing and delivery of the 100 million doses, the...

Moderna’s experimental coronavirus vaccine built immunity in monkeys and protected them from becoming infected, according to the results of a new trial study. Monkeys that received two-doses of the vaccination were protected from infections in the lungs and nose, according to the Cambridge-based bio-tech company’s website. When given the vaccine, mRNA-1273, the monkeys showed a “robust immune response and...

The head of the Chinese Center for Disease Control and Prevention says he has been injected with an experimental coronavirus vaccine in an attempt to persuade the public to follow suit when one is approved

President Donald Trump’s handling of the coronavirus pandemic put his political fate in grave jeopardy

Tens of thousands of volunteers will take part in the study, with results being reported as soon as November.

The world’s biggest COVID-19 vaccine test got underway Monday with the first of 30,000 planned volunteers

Early data shows a vaccine under development by Oxford University and AstraZeneca triggers antibodies and the production of virus-fighting T-cells.

Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot

Western governments are accusing hackers believed to be part of the Russian intelligence services of trying to steal information about a coronavirus vaccine

An experimental coronavirus vaccine showed a “robust” immune response, Moderna announced Tuesday, producing promising data that the vaccine may give some protection against the coronavirus. In the early stage of the Cambridge-based biotech company’s human trial, all 45 patients produced antibodies after getting two shots, which scientists believe is important for building immunity. In the trial, each participant received a...

Cambridge-based biotech company Moderna is the first in the United States to announce a start date for its final testing of a potential coronavirus vaccine.

An experimental vaccine may give some protection against the coronavirus, data from early stages of a human trial by Cambridge-based biotech company Moderna shows.

Moderna’s shares soared after the company said its potential vaccine to prevent Covid-19 produced a “robust” immune response in all 45 patients in its early stage human trial, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine. Moderna’s stock rose more than 16% in after-hours trading on the news.  All 45 patients produced…

Politicians and public health leaders have publicly committed to equitably sharing any coronavirus vaccine that works, but the top global initiative to make that happen may allow rich countries to reinforce their own stockpiles while making fewer doses available for poor ones

When precious vats of COVID-19 vaccine are finally ready, the ability to jab the lifesaving solution into the arms of Americans will require hundreds of millions of injections

Six months after COVID-19 started spreading around the globe, desperation rather than information is still driving many decisions about how to treat the disease

Peter Pitts, the former FDA Associate Commissioner, said industry, academia and government are working together to make an effective coronavirus vaccine available by early 2021. But the rollout is expected to be complicated, with more than one vaccine likely available and questions about which groups should be prioritized to get the vaccine first.